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(57) ABSTRACT 
A method is presented for determining diastolic intracranial 
pressure (ICP) in a patient. A first change in the length of a 
path across the skull of the patient caused by a known 
change in ICP is measured and used to determine an 
elasticity constant for the patient. Next, a second change in 
the length of the path across the patient’s skull occurring 
between systolic and diastolic portions of the patient’s 
heartbeat is measured. The patient’s diastolic ICP is a 
function of the elasticity constant and the second change. 
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NON-INVASIVE METHOD OF 
DETERMINING DIASTOLIC 
INTRACRANIAL PRESSURE 
C W M  OF BENEFIT OF PROVISIONAL 
APPLI CAT1 ON 
describes pressure and volume relationships in the cranial 
complex. While the various relationships differ, it is gener- 
ally accepted that increases in diastolic ICP (i.e., increases in 
ICP occurring during the diastolic rhythm of one’s 
5 heartbeat) generate intracranial hypertension that affects the 
viability and function of the human brain. 
Given the above, monitoring of diastolic ICP is of sig- 
nificant diagnostic and post-operative importance for 
patients with cranial injuries, pathologies or other conditions 
that may affect the pressure of the subarachnoidal fluid 
around the brain, and for patients who have undergone brain 
surgery. In general, ICP has traditionally been measured and 
monitored by means of a pressure sensor inserted through 
the skull into the brain. Usually a hole is drilled in the skull 
of the United States G~~~~~~~~~ and may be manufactured 1s and a catheter with a pressure sensor is inserted into the 
poses without the payment of any royalties thereon or rate is not suitable for long-term monitoring because an open 
wound must be maintained in the skull. Antibiotics are only therefor. 
partially effective in treating cranial infections so the pres- 
2o sure sensor can only be left in place for two weeks or less. 
Long-term monitoring of ICP is currently achieved by 
implanting a pressure sensor and transmitter into the brain. 
Pursuant to 35 U.S.C. Section 119, the benefit of priority 
from Provisional application 601371,601, with a filing date 
of APr. 8, 2002, is claimed for this non-Provisiona1 aPPli- 
cation. 
ORIGIN OF THE INVENTION 
ne invention described herein was made by employees 
and used by or for the Government for governmental pur- brain fluid. This known procedure, while simple and accu- 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This patent is co-pending with One The ICP is thereafter monitored by means of a receiver 
patent ‘‘NoN-lNVASIVE OF located outside the skull. However, this solution is not 
INTRACRANIAL PRES- 2s preferred because it includes the risks associated with 
implanting anything in the brain, and because of the prob- 
lems associated with providing power to an implanted 
SURE’ (NASA Case No. LAR 16510-1)3 by the Same 
inventors as this patent application. 
transmitter. 
A varietv of non-invasive svstems and/or methods of BACKGROUND OF THE INVENTION 
1. Field of the Invention 30 measuring relative changes in ICP have been described in 
091493,044, 101094,023, and 101121,932. However, none of 
This invention relates to determination of intracranial each Of u.s. patent Ser. Nos. 091459,384, 
pressure. More specifically, the invention is a non-invasive 
a patient. diastolic ICP. 
method for determining the diastolic intracranial pressure in these provide for the measurement Or determination Of a 
SUMMARY OF THE INVENTION 2. Description of the Related Art 
Bone tissue is the most rigid of all animal tissues. The Accordingly, it is an object of the present invention to 
skull bone surrounds and protects one’s cranial complex provide a method of determining diastolic ICP in a non- 
which includes the brain and cerebrospinal fluid (CSF) invasive fashion. 
surrounding the brain. The human brain and the spinal cord 4o Another object of the present invention is to provide a 
are immersed in CSF which is continuously generated and method of determining diastolic I c p  that minimizes the 
reabsorbed by the body. The CSF is contained in a mem- number of procedures used, 
brane covering the inside of the skull and the spinal cord Other objects and advantages of the present invention will 
which terminates in a sack located at the sacrum. The brain become obvious hereinafter in the specification and 
and the membrane containing the CSF also contain blood 4s drawings, 
vessels, which are in direct communication with the CSF In accordance with the present invention, a method is 
blood volume in these blood vessels varies rhythmically (Icp) in a patient, A first change in the length of any path 
with the heartbeat thereby causing corresponding oscilla- the skull of the patient caused by a known change in 
tions in the intracranial pressure (ICP). The collective com- so I c p  is measured, This first change relative to the known 
pliance (i.e., the ability to increase in volume with increasing change in Icp is indicative of an elasticity constant for the 
3s 
and add to the Of the system. The presented for determining diastolic intracranial pressure 
pressure) Of the 
the pressure regu1ation needed for proper 
and CSF is too to accommodate 
Of 
cord. Hence, pressure 
patient. Next, a second change in the length of the path 
across the patient’s skull occurring between systolic and 
diastolic portions of the patient’s heartbeat is measured. The within the brain and 
within the cranial complex is controlled by the compliance ss patient’s diastolic Icp is a function of the elasticity constant 
of the brain’s venous bed in association with the creation and for the path and the second change in the length of the path 
removal of CSF by specialized structures within the brain. 
Pressure is regulated by rate of production of CSF by the 
BRIEF DESCRIPTION OF THE DRAWINGS choroid plexus, and rate of removal of cerebrospinal fluid by 
the arachnoid villi. These rates therefore play a crucial role 60 
in blood flow regulation, while also relating to disease and 
pathologies which can occur. Acomplex interaction between 
the blood vessels and ICP accomplishes the needed regula- 
tion of blood flow in brain tissue. 
Substantial effort has been devoted to understanding the 65 
dynamics of pulsatile effects on ICP. Towards this end, many 
investigators have developed an “equation of state” which 
the patient’s skull, 
FIG. 1 is a schematic view of the skull and brain of a 
patient with the brain being coupled to the patient’s heart; 
FIG. 2 is a graphical view of a model relating pulsatile 
variations in ICP to the mean diastolic ICP for a typical 
human CSF system; 
FIG. 3 is a schematic view of a system that can be used 
to measure1monitor skull expansion in a patient for use by 
the method of the present invention; 
3 
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FIG. 4 is a side view of a patient lying in a supine position 
on a tiltable bed for mechanical manipulation of the patient 
as a means to induceicause known changes in intracranial 
pressure (ICP) in the patient; and 
FIG. 5 is a graph of a patient’s pulsatile skull expansion 
versus time as measured by, for example, the system in FIG. 
3. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Referring now to the drawings, and more particularly to 
FIG. 1, a patient’s skull 10 is illustrated with his brain 
referenced by numeral 12. As is well known, brain 12 is a 
venous structure that is coupled to the patient’s heart 14 and, 
therefore, undergoes systolic-diastolic changes in blood 
pressure. Surrounding brain 12 is the patient’s cerebrospinal 
fluid (CSF) 16, the pressure of which is known as intracra- 
nial pressure or ICP as it will be referenced herein. 
Skull 10 tends to expand and contract with changes in 
ICP. However, the compliance (i.e., the ability of skull 10 to 
expand with increasing ICP) of skull 10 is not sufficient to 
accommodate the pressure regulation needed for proper 
circulation of blood within brain 12 and the patient’s CSF 
system (not shown). Accordingly, pressure within skull 10 is 
controlled by compliance of the brain’s venous bed in 
association with the additioniremoval of CSF 16. 
As mentioned above, substantial effort has been devoted 
to understanding the dynamics of pulsatile effects of ICP. 
The present invention makes use of a hydrodynamic model 
that describes a numerical relationship between pulsatile 
variations in ICP (i.e., difference between systolic ICP and 
diastolic ICP) and a mean diastolic ICP. The hydrodynamic 
model is described in detail by Mauro Ursino in “A Math- 
ematical Study of Human Intracranial Hydrodynamics Part 
1-The Cerebrospinal Fluid Pulse Pressure,” Annals of Bio- 
medical Engineering, Volume 16, pages 379401,  1988, 
which article is incorporated herein by reference as if set 
forth in its entirety. The graphical version of the hydrody- 
namic model relating the pulsatile variations in ICP to the 
mean diastolic ICP is shown for a general human population 
in FIG. 2 herein. When a best-fit curve is applied to the 
values in FIG. 2, a power law relationship between pulsatile 
variations in ICP and a mean diastolic ICP can be written 
mathematically as 
ICP,,,=A(KAX)~ (1) 
where ICP,, is diastolic ICP for a patient at a measure- 
ment point in time, K is an elasticity constant to be deter- 
mined for the patient by the present invention, Ax is the 
amount of linear skull expansion (i.e., path length change) 
occurring (at the “measurement point in time”) between the 
systolic and diastolic points in the heartbeat of the patient, 
and A and B are constants determined from a best fit to the 
general population data in FIG. 2. For example, for the curve 
illustrated, A is 5.6957 and B is 0.77312. However, it is to 
be understood that some variation in A and B will occur 
depending on the “best-fit curve” used. Accordingly, par- 
ticular choices for A and B are not limitations of the present 
invention. 
In addition to the above-cited work by Ursino, the present 
invention takes note of the fact that the skull responds to 
pulsatile changes in ICP with a very slight increase in 
volume referred to hereinafter as pulsatile skull expansion, 
i.e., the amount of skull expansion between the systole and 
diastole portions of a heartbeat. The volume change result- 
ing from pulsatile skull expansion can be viewed as a change 
in path length measured, for example, across the skull. 
The elasticity constant K for a given patient can be 
K=AICPIAl (2) 
where AICP is a static ICP change caused by a manipulation 
of the patient and A1 is the resultant skull expansion asso- 
ciated therewith. The resultant skull expansion A1 is viewed 
herein as a change in path length measured, for example, 
across the skull. Once the elasticity constant K is established 
for a given patient, equation (1) provides for the determi- 
lo nation of the mean diastolic ICP or ICP,, using a mea- 
surement of pulsatile skull expansion Ax which will be 
explained further below. 
Before describing the details of the method of the present 
invention, it is to be understood that the inducement of 
1s changes in ICP and/or the measurement of changes in ICP 
can be carried out in a variety of ways without departing 
from the scope of the present invention. For example, 
intentionally induced changes in ICP can be brought about 
by mechanical manipulation of the patient (e.g., pressure 
20 applied to the skull, through the use of a tilt bed, immersion 
of the patient in a negative pressure chamber, etc.) or by 
chemical manipulation of the patient (e.g., giving the patient 
drugs to alter blood gas concentration, decrease production 
of CSF, increase the uptake rate of CSF, etc.). Changes in 
zs ICP can be measuredidetermined by a variety of acoustic 
systems (e.g., pulse-echo, pitch-catch, etc.) such as the 
constant frequency pulsed phase locked-loop ultrasonic 
measuring system described in U.S. Pat. No. 5,214,955, 
which patent is incorporated herein by reference as if set 
By way of a non-limiting example, FIG. 2 illustrates a 
system 20 that can be used to determine elasticity constant 
K and monitor pulsatile skull expansion Ax of a patient. 
System 20 includes an adjustable headband 22 hinged at its 
35 central portion as indicated by dashed line 24. Pressure pads 
26 and 28 are positioned at either end of headband 22 such 
that, when headband 22 is fitted over a patient’s skull 10, 
pressure pads 26 and 28 are positioned at approximately 
diametrically opposed positions about skull 10. Each of 
40 pressure pads 26 and 28 can define a conforming pad (e.g., 
a gel-filled pad) to assure uniform contact with skull 10. 
Mounted to pressure pad 28 is a transducer 30 capable of 
transmitting and receiving acoustic signals for use in a 
pulse-echo measurement approach. Signals are provided to 
45 transducer 30 by a control system 32 and acoustic echoes 
received by transducer 30 are provided to control system 32. 
In the pulse-echo approach, pressure pad 26 can be con- 
structed as an anechoic chamber to reduce reflections from 
the skin air interface adjacent the side of the skull subjected 
SO to the acoustic signals. Separate transmission and reception 
transducers could also be used for either pulse-echo or 
pitch-catch measurement approaches. For example, in terms 
of a pitch-catch measurement approach, transducer 30 could 
be a dedicated transmitter and a transducer 31 (shown in 
ss phantom) could be a dedicated receiver mounted on pad 26. 
Aforce device 34 is coupled to headband 22 on either side 
of hinge 24. Force device 34 is any controllable device 
capable of drawing headband 22 together about hinge 24 
such that an increasing pressure is applied to skull 10 via 
60 each of pads 26 and 28. Examples of force device 34 can 
include, but are not limited to, solenoids, screw drives, 
hydraulic drives, gear drives, etc., where system response is 
linear. That is, force device 34 should be “linear” in its 
expansion and contraction characteristics as it follows skull 
65 expansion. Such linearity is manifested by a force device 
having a constant (i.e., linear) and known stiffness (or 
modulus). 
determined in accordance with 
30 forth in its entirety. 
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can be provided at each of pressure pads 26 and 28, 
respectively. The pressure readings can be used by control 
system 32 as a feedback control for force device 34. Pressure 
outputs can also be displayed on a display 40. 
To monitor skull expansion using the pulse-echo 
approach, headband 22 is placed on skull 10 such that pads 
26 and 28 are in contact with the patient’s skin 11 adjacent 
to skull 10. With respect to pad 28, note that transducer 30, 
as well as portions of pad 28 to the sides of transducer 30, 
will contact skin 11. This ensures good coupling of acoustic 
signals transmitted into skull 10 from transducer 30 as well 
5 6 
Control of force device 34 can be maintained by control 
system 32 which can be entirely automatic or can include 
means for accepting manual inputs. To monitor the amount 
of pressure applied to skull 10, pressure sensors 36 and 38 
from FIG. 4 for clarity of illustration. With bed 102 tilted by 
an angle (I with the legs of patient 100 higher than skull 10, 
a change (increase in this case) in ICP (or AICP) is given as 




where p is the mass density of spinal fluid, g is the earth’s 
gravitational constant, L is the distance from the center of 
the patient’s sacrum (the location of which is indicated at S) 
to the center of skull 10, and (I is the amount of tilt angle of 
bed 102 relative to a (horizontal) datum 104. The present 
invention is not limited to a measurement of L that originates 
at the patient’s sacrum. For example, L could be measured 
with respect to another reference point such as the point at 
which pressure in the spinal column does not change with tilt 
angle. Thus, for any given patient with a knownimeasurable 
distance L. AICP can be calculated usinn eauation (3). a a 1  \ I  
as good coupling of acoustic signal reflections from skull 10 As mentioned above, changes in skull expansion mea- 
to transducer 30. sured by system 20 are essentially defined by changes in 
In general, system 20 monitors skull expansion in accor- path length A1 that the acoustic signal travels between its 
dance with the teachings of U.S. Pat. No. 5,214,955. That is, transmission and reception locations. That is, between any 
system 20 measures path length changes as a function of 20 two measurement points in time, the path length “1” that the 
phase difference between the acoustic signal transmitted into acoustic signal travels gets longer in the case of positive 
skull 10 and the acoustic signal measured at a detection skull expansion or shorter in the case of negative skull 
location at two different points in time. As mentioned above, expansion (i.e., skull contraction). Path length 1 could be 
the detection location can be: i) the same as the transmission defined by one or more paths across skull 10 depending on 
location when a single transmissionireception transducer 30 zs the number of such lengths traversed by the acoustic signal 
is used, ii) adjacent the transmission location if a dedicated between its transmission and reception locations. Thus, the 
reception transducer is mounted adjacent transducer 30, iii) change in path length A1 is measured between the two points 
at another location that is spaced apart from the transmission in time defined by the start of the “manipulation” causing the 
location, e.g., at a location diametrically-opposed to the change in ICP and the completion of the “manipulation.” For 
transmission location as would be the case if dedicated 30 example, using the tilt bed method, A1 would be the change 
reception transducer 31 were used. 
Prior to monitoring skull expansion using system 20, it 
may be desirable to establish and apply a differential pres- 
sure bias to skull 10 at each of the transmission, reception 
and, if applicable, reflection locations about skull 10 in order 
to reduce or eliminate the effects associated with pulsatile 
blood perfusion, i.e., the small amount of systolic diastolic 
blood located between the patient’s skin and skull. The 
amount of differential pressure required to reduce or elimi- 
nate the influence of aulsatile blood aerfusion can be deter- 
occurring between first and second angular positions of the 
tilt bed. Using the known change AICP and the correspond- 
ing path length change Al, the elasticity constant K is 
determined in accordance with equation (2). 
With elasticity constant K now being known, the present 
invention need only measure pulsatile skull expansion Ax 
and use equation (1) to determine diastolic ICP or ICPDIAs. 
Pulsatile skull expansion Ax can be measured using system 
20. For example, a representative output of system 20 is 
40 illustrated in FIG. 5 where ahase difference is measured in 
35 
mined by monitoring skull expansion as a function of terms of an output voltage. Note that in tests of the present 
applied differential pressures. Initially, the slope of a plot of invention, the phase difference waveform depicted in FIG. 5 
these two parameters will be fairly steep. However, the slope correlated well with the patient’s pulse waveform. 
will level off to a constant once the effects of pulsatile blood Accordingly, a peak-to-valley measurement of the wave- 
aerfusion are reducedieliminated. Note that this stea is not 45 form in FIG. 5 is indicative of aulsatile skull exaansion Ax. 
required if acoustic signals can be coupled directly toifrom 
the skull as opposed to indirectly through the patient’s skin. 
The effects of blood perfusion may be reduced or elimi- 
nated as described above. Then, the patient (with headband 
22 still in place) is “manipulated” to bring about known 
changes in ICP without a corresponding change in pulsatile 
blood perfusion. Such manipulations can be mechanical or 
chemical in nature. Mechanical manipulations can include 
the use of additional pressure being applied by force device 
34 of system 20, the use of a tilt bed while system 20 
maintains its differential pressure bias, the immersion of the 
The conversion of a peak-to-valley voltage to a pulsatile 
skull expansion Ax is made possible by calibration of system 
20 as would be understood by one of ordinary skill in the art. 
The advantages of the present invention are numerous. 
SO Determination of diastolic ICP is determined through the use 
of easily taken measurements. The process is non-invasive 
in nature and can, therefore, be used for both one-time and 
longer term monitoring scenarios. Thus, the present inven- 
tion will find great utility in both critical and non-critical 
ss ICP-related pathologies as well as other medical applica- 
tions requiring knowledge of diastolic ICP. 
patient in a negative pressure chamber, etc. Chemical Although the invention has been described relative to a 
manipulations include drug intervention techniques for specific embodiment thereof, there are numerous variations 
increasingidecreasing ICP. and modifications that will be readily apparent to those 
As a result of such patient manipulations, known changes 60 skilled in the art in light of the above teachings. For 
in ICP (or AICP) are brought about while corresponding example, rather than using the tilt bed approach to causing 
changes in skull expansion (or Al) are monitored. The known changes in ICP, system 20 could be used to apply 
causing of known changes in ICP can be brought about by incremental increases in headband pressure to bring about 
the tilt bediangle method, which has been described in U.S. changes in path length to permit calibration. It is therefore 
Pat. No. 5,617,873. Briefly, as shown in FIG. 4, a patient 100 65 to be understood that, within the scope of the appended 
lies supine on a tiltable bed 102. Note that while system 20 claims, the invention may be practiced other than as spe- 
would remain coupled to patient 100, it has been omitted cifically described. 
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What is claimed as new and desired to be secured by 
1. A method of determining diastolic intracranial pressure 
measuring a first change in the length of a path across the 
skull of the patient caused by a known change in ICP 
in the patient, wherein said first change in the length of 
said path relative to said known change in ICP is 
indicative of an elasticity constant for the patient; and 
measuring a second change in the length of said path 
occurring between systolic and diastolic portions of a 
heartbeat of the patient, wherein a diastolic ICP is a 
function of said elasticity constant and said second 
change in the length of said path. 
2. A method according to claim 1 wherein each of said 
steps of measuring comprises the steps of  
coupling an acoustic signal to a first location on the 
patient’s skin adjacent the skull of the patient; 
detecting said acoustic signal at a second location on the 
patient’s skin adjacent the skull of the patient; and 
measuring a phase difference between said acoustic signal 
so-coupled at said first location and said acoustic signal 
so-detected at said second location, wherein said phase 
difference is indicative of one of said first change and 
said second change. 
3. A method according to claim 2 further comprising the 
step of applying pressure to the patient’s skin at each of said 
first location and said second location prior to said steps of 
coupling and detecting, wherein pulsatile blood perfusion at 
said first location and said second location is reduced. 
4. A method according to claim 2 wherein said first 
location and said second location are approximately 
diametrically-opposed to one another on either side of the 
skull of the patient. 
5. A method according to claim 2 wherein said first 
location and said second location are approximately the 
same location. 
6. A method according to claim 1 wherein said known 
change in ICP is induced by the step of manipulating the 
patient in a mechanical fashion. 
7. A method according to claim 1 wherein said known 
change in ICP is induced by the step of manipulating the 
patient in a chemical fashion. 
8. A method of determining diastolic ICP in a patient, 
comprising the steps o f  
measuring a first change A1 in the length of a path across 
the skull of the patient caused by a known change AICP 
in ICP in the patient, wherein AICPIAl defines an 
elasticity constant K for the patient; and 
measuring a second change Ax in the length of said path 
occurring between systolic and diastolic portions of a 
heartbeat of the patient, wherein a diastolic ICP is equal 
to A(KAx)~, where A and B are constants derived from 
a data relationship between pulsatile variations in ICP 
and a mean diastolic ICP, wherein said data relationship 
is defined for a general human population. 
9. A method according to claim 8 wherein each of said 
coupling an acoustic signal to a first location on the 
patient’s skin adjacent the skull of the patient; 
detecting said acoustic signal at a second location on the 
patient’s skin adjacent the skull of the patient; and 
measuring a phase difference between said acoustic signal 
so-coupled at said first location and said acoustic signal 
so-detected at said second location, wherein said phase 
difference is indicative of one of said first change and 
said second change. 
Letters Patent of the United States is: 
(ICP) in a patient, comprising the steps of  















10. A method according to claim 9 further comprising the 
step of applying pressure to the patient’s skin at each of said 
first location and said second location prior to said steps of 
coupling and detecting, wherein pulsatile blood perfusion at 
said first location and said second location is reduced. 
11. A method according to claim 9 wherein said first 
location and said second location are approximately 
diametrically-opposed to one another on either side of the 
skull of the patient. 
12. A method according to claim 9 wherein said first 
location and said second location are approximately the 
same location. 
13. A method according to claim 8 wherein said known 
change in ICP is induced by the step of manipulating the 
patient in a mechanical fashion. 
14. A method according to claim 8 wherein said known 
change in ICP is induced by the step of manipulating the 
patient in a chemical fashion. 
15. A method of determining diastolic ICP in a patient, 
comprising the steps of  
coupling an acoustic signal to a first location on the 
detecting said acoustic signal at a second location on the 
inducing a known change in ICP in the patient; 
measuring a first phase difference between said acoustic 
signal so-coupled at said first location and said acoustic 
signal so-detected at said second location, said first 
phase difference being caused by said known change in 
ICP, wherein said first phase difference is indicative of 
a first change in the length of a path across the skull of 
the patient, and wherein said first change in the length 
of said path relative to said known change in ICP is 
indicative of an elasticity constant for the patient; 
repeating said steps of coupling and detecting; and 
measuring, during said step of repeating, a second phase 
difference between said acoustic signal so-coupled at 
said first location and said acoustic signal so-detected at 
said second location, said second phase difference 
occurring between systolic and diastolic portions of a 
heartbeat of the patient, wherein said second phase 
difference is indicative of a second change in the length 
of said path occurring between said systolic and dias- 
tolic portions, wherein a diastolic ICP is a function of 
said elasticity constant and said second change in the 
length of said path. 
16. A method according to claim 15 further comprising 
the step of applying pressure to the patient’s skin at each of 
said first location and said second location prior to said steps 
of coupling and detecting, wherein pulsatile blood perfusion 
at said first location and said second location is reduced. 
17. A method according to claim 15 wherein said first 
location and said second location are approximately 
diametrically-opposed to one another on either side of the 
skull of the patient. 
18. A method according to claim 15 wherein said first 
location and said second location are approximately the 
same location. 
19. A method according to claim 15 wherein said known 
change in ICP is induced by the step of manipulating the 
patient in a mechanical fashion. 
20. A method according to claim 15 wherein said known 
change in ICP is induced by the step of manipulating the 
patient in a chemical fashion. 
patient’s skin adjacent the skull of the patient; 
patient’s skin adjacent the skull of the patient; 
* * * * *  
